·SEC EDGARLow
Spoor Johan M. purchased $38K of CATX
Spoor Johan M. (Chief Executive Officer) purchased 47,000 shares of Perspective Therapeutics, Inc. (CATX) at $0.81 on 2026-11-11.
StockNYSE · US · USDHealthcare · Medical Devices
$CATX
Perspective Therapeutics, Inc.
Perspective Therapeutics is a radiopharmaceutical development company focused on cancer treatments. It uses the alpha-emitting isotope Lead-212 (212Pb) and targeting molecules to deliver radiation to cancer cells, and develops related imaging diagnostics using Lead-203 (203Pb) to help identify tumors and guide treatment. Its theranostic platform combines imaging and therapy using the same targeting molecules. The company’s clinical programs include VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma and PSV359 for solid tumors; all three are in Phase 1/2a imaging and therapy trials in the U.S. Perspective Therapeutics is also developing proprietary 212Pb generator technologies and a regional network of finishing facilities to supply patient-ready product candidates for clinical trials and commercial operations. It retains global development and commercialization rights to its product candidates.
AlphAI earnings readQ3 FY2026 · NOV 9Perspective Therapeutics reports Q3 2026 net loss of $32.4 million as R&D expense rises to $26.1 million; cash, equivalents and short-term investments about $202 millionVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $CATXvia TradingView
AI sentiment · 7d13 articles
- Bullish
- 7
- Neutral
- 2
- Bearish
- 4
Insider · 30dAll trades →
- Buys
- $38K 1 txs
- Sells
- — 0 txs
Spoor Johan M.1× · $38K
10b5-1 share of filings0%
Top stories · $CATXMore →
·investing.com
BMO reiterates Outperform on Perspective Therapeutics stock
BMO Capital reiterated an Outperform rating on Perspective Therapeutics (CATX) with a $11.00 price target, citing positive updates from recent conferences. The company extended its cash runway to 2028. CATX stock is down 69% YTD, trading at $0.86. Other analysts have mixed views, with RBC downgrading to Sector Perform and a $4.00 target, while BTIG maintained a Buy rating with a $14.00 target.
·investing.com
Truist cuts Perspective Therapeutics stock price target on timeline
Truist Securities reduced its price target for Perspective Therapeutics (NYSE: CATX) to $8.00 from $11.00, citing clinical trial timelines. The stock is down 77% in six months. Other analysts have mixed views, with targets ranging from $4.00 to $14.00. The company has cash runway into 2028 but is burning cash quickly.
CATX sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 13 news stories mentioning CATX (Perspective Therapeutics, Inc.). Coverage has skewed bullish: 7 bullish, 2 neutral, and 4 bearish.
Recent CATX coverage spans financial news, earnings and insider activity.
In the last 30 days, CATX insiders filed 1 SEC Form 4 transaction — 1 purchase ($38K) and no sales. The most active reporter was Spoor Johan M., Chief Executive Officer, with 1 filing.
What's driving CATX
Small insider purchase may signal confidence but size is modest.
Analyst rating upgrade may support modest upside pressure.
Analyst target cut suggests downside pressure on the stock.
Target cut suggests the market may reprice the stock lower.
Earnings miss with sharply lower revenue likely increases downside pressure and raises concerns about near-term operating trajectory.
AlphAI scores every news story that mentions CATX with an AI model for sentiment and relevance, and aggregates insider trades from Perspective Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CATX
Score
Spoor Johan M. purchased $38K of CATX
Spoor Johan M. (Chief Executive Officer) purchased 47,000 shares of Perspective Therapeutics, Inc. (CATX) at $0.81 on 2026-11-11.
BMO reiterates Outperform on Perspective Therapeutics stock
BMO Capital reiterated an Outperform rating on Perspective Therapeutics (CATX) with a $11.00 price target, citing positive updates from recent conferences. The company extended its cash runway to 2028. CATX stock is down 69% YTD, trading at $0.86. Other analysts have mixed views, with RBC downgrading to Sector Perform and a $4.00 target, while BTIG maintained a Buy rating with a $14.00 target.
Truist cuts Perspective Therapeutics stock price target on timeline
Truist Securities reduced its price target for Perspective Therapeutics (NYSE: CATX) to $8.00 from $11.00, citing clinical trial timelines. The stock is down 77% in six months. Other analysts have mixed views, with targets ranging from $4.00 to $14.00. The company has cash runway into 2028 but is burning cash quickly.
Wedbush lowers Perspective Therapeutics stock price target to $7
Wedbush reduced its price target for Perspective Therapeutics (NYSE:CATX) to $7 from $9, citing adjusted capital raise assumptions. The stock is down 69% YTD. Analysts have mixed views, with targets ranging from $4 to $14. The company's cash position and burn rate are noted.
Perspective Therapeutics earnings missed by $0.03, revenue fell short of estimates
Perspective Therapeutics (CATX) reported Q1 EPS of -$0.27, missing estimates by $0.03, with revenue of $20K, below the $74.68K consensus. The stock is down 72.4% over 3 months and 61.46% over 12 months. InvestingPro rates its financial health as weak.
Perspective Therapeutics: Q3 Earnings Snapshot
Perspective Therapeutics (CATX) reported a Q3 loss of $32.4M, or 27 cents per share, missing analyst expectations of a 24 cents per share loss. The company generated $20,000 in revenue. CATX develops isotope-based medical products.
Perspective Therapeutics, Inc. (CATX): Reports 3Q 2026 Results
Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results • Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced…
Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 • Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease con
Perspective Therapeutics (CATX) Reports 2 Partial Responses in 8 Patients at Focus Dose
Perspective Therapeutics (CATX) reported interim Phase 1/2a data for VMT01, showing 2 partial responses in 8 patients at the 3.0 mCi dose, with a 75% disease control rate. No dose-limiting toxicities or treatment-related serious adverse events were reported across 20 patients. The company continues dose optimization for future development.
Experimental melanoma treatment shrank tumors in 2 of 8 patients; one response remained after about 40 weeks.
Perspective Therapeutics (CATX) reported interim Phase 1/2a trial results for its melanoma treatment, lapemelanotide. Two of eight patients at the 3.0 mCi dose showed tumor shrinkage, with one response lasting ~40 weeks. No serious adverse events were reported. The company plans to continue dose optimization and development.